Although the meta-analysis of 27 randomized clinical trials including 19,930 COVID-19 patients in total did show lower 28-day mortality with IL-6 antagonists administration [45], high variability of the treatment outcome suggests that broader-acting interventions against COVID-19-associated cytokine storm may be needed to achieve a reliable benefit. The gene discussed is IL6; the disease is COVID-19.